Home › Funds › Novo Holdings A/S › ELVN

Novo Holdings A/S position in ELVN

ENLIVEN THERAPEUTICS INC · Health Care

Novo Holdings A/S reported holding 1,000,000 shares of ELVN (ENLIVEN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$45.8M, representing 3.08% of its reported portfolio and ranking #9 among its reported holdings. Novo Holdings A/S has disclosed ELVN holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

Latest position (Q3 2026)1.00M sh
Reported value held$45.84M
Portfolio Weight3.08%
First reportedQ2 2025
Last changeHold
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Novo Holdings A/S's ELVN position evolved

Novo Holdings A/S first disclosed a stake in ELVN in Q2 2025 at 1,084,432 shares (US$21.8M). The position peaked in Q2 2026 at 1,000,000 shares, worth US$50.8M. Across 6 filings, Novo Holdings A/S increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,000,000 shares valued at US$45.8M. Notable position changes include a 32% increase in Q3 2025 (shares fell 25% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 1.08M $21.75M New
Q3 2025 1.43M $29.20M Add
Q4 2025 1.48M $22.79M Add
Q1 2026 1.28M $50.18M Reduce
Q2 2026 1.00M $50.75M Reduce
Q3 2026 1.00M $45.84M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ELVN and 13F data

ELVN (ENLIVEN THERAPEUTICS INC) is a Health Care company. 56 other funds we track also report a position in ELVN — the largest reported positions include ORBIMED ADVISORS LLC (US$310.6M), Polar Capital Holdings Plc (US$294.5M), Commodore Capital LP (US$150.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ELVN

All ELVN fund holders →

FAQ

How long has Novo Holdings A/S held ELVN?

Novo Holdings A/S has disclosed ELVN holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

What is Novo Holdings A/S's current position in ELVN?

As of Q3 2026, Novo Holdings A/S holds 1.00M shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $45.84M, representing 3.08% of its reported portfolio and ranking #9.

Has Novo Holdings A/S been buying or selling ELVN?

In the latest 13F filing (Q3 2026), Novo Holdings A/S held unchanged its position in ELVN. The position peaked in Q2 2026 at 1.00M shares.

Which other funds hold ELVN?

Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Commodore Capital LP, among 56 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.